132 related articles for article (PubMed ID: 35364255)
1. In situ gelling system for sustained intraarticular delivery of bupivacaine and ketorolac in sheep.
Abdeltawab H; Bolam SM; Jaiswal JK; McGlashan SR; Young SW; Hill A; Svirskis D; Sharma M
Eur J Pharm Biopharm; 2022 May; 174():35-46. PubMed ID: 35364255
[TBL] [Abstract][Full Text] [Related]
2. Injectable thermoresponsive gels offer sustained dual release of bupivacaine hydrochloride and ketorolac tromethamine for up to two weeks.
Abdeltawab H; Svirskis D; Boyd BJ; Hill A; Sharma M
Int J Pharm; 2021 Jul; 604():120748. PubMed ID: 34051318
[TBL] [Abstract][Full Text] [Related]
3. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.
M A Fathalla Z; Vangala A; Longman M; Khaled KA; Hussein AK; El-Garhy OH; Alany RG
Eur J Pharm Biopharm; 2017 May; 114():119-134. PubMed ID: 28126392
[TBL] [Abstract][Full Text] [Related]
4. In vitro and ex vivo characterisation of an in situ gelling formulation for sustained lidocaine release with potential use following knee arthroplasty.
Sharma M; Chandramouli K; Curley L; Pontre B; Reilly K; Munro J; Hill A; Young S; Svirskis D
Drug Deliv Transl Res; 2018 Jun; 8(3):820-829. PubMed ID: 29411295
[TBL] [Abstract][Full Text] [Related]
5. Injectable thermosensitive gelling delivery system for the sustained release of lidocaine.
Svirskis D; Chandramouli K; Bhusal P; Wu Z; Alphonso J; Chow J; Patel D; Ramakrishna R; Yeo SJ; Stowers R; Hill A; Munro J; Young SW; Sharma M
Ther Deliv; 2016 Jun; 7(6):359-68. PubMed ID: 27250538
[TBL] [Abstract][Full Text] [Related]
6. Stability and compatibility of admixtures containing bupivacaine hydrochloride and ketorolac tromethamine for parenteral use.
Abdeltawab H; Jaiswal JK; Young SW; Svirskis D; Hill A; Sharma M
Eur J Hosp Pharm; 2023 Mar; 30(e1):e48-e54. PubMed ID: 34663584
[TBL] [Abstract][Full Text] [Related]
7. Postoperative analgesia for outpatient arthroscopic knee sugery with intraarticular bupivacaine and ketorolac.
Reuben SS; Connelly NR
Anesth Analg; 1995 Jun; 80(6):1154-7. PubMed ID: 7762844
[TBL] [Abstract][Full Text] [Related]
8. Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation.
Hulambukie E; Abdeltawab H; Duarah S; Svirskis D; Sharma M
Gels; 2022 Feb; 8(2):. PubMed ID: 35200495
[TBL] [Abstract][Full Text] [Related]
9. Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in situ hydrogels.
Li X; Du L; Chen X; Ge P; Wang Y; Fu Y; Sun H; Jiang Q; Jin Y
Int J Pharm; 2015 Jul; 489(1-2):252-60. PubMed ID: 25957699
[TBL] [Abstract][Full Text] [Related]
10. Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan.
Li C; Li C; Liu Z; Li Q; Yan X; Liu Y; Lu W
Int J Pharm; 2014 Oct; 474(1-2):123-33. PubMed ID: 25138250
[TBL] [Abstract][Full Text] [Related]
11. Formulation strategies to modulate drug release from poloxamer based in situ gelling systems.
Abdeltawab H; Svirskis D; Sharma M
Expert Opin Drug Deliv; 2020 Apr; 17(4):495-509. PubMed ID: 32067500
[No Abstract] [Full Text] [Related]
12. Novel in-situ gel for intravesical administration of ketorolac.
Sherif AY; Mahrous GM; Alanazi FK
Saudi Pharm J; 2018 Sep; 26(6):845-851. PubMed ID: 30202226
[TBL] [Abstract][Full Text] [Related]
13. Sustained release of ketorolac tromethamine from poloxamer 407/cellulose nanofibrils graft nanocollagen based ophthalmic formulations.
Orasugh JT; Dutta S; Das D; Pal C; Zaman A; Das S; Dutta K; Banerjee R; Ghosh SK; Chattopadhyay D
Int J Biol Macromol; 2019 Nov; 140():441-453. PubMed ID: 31437512
[TBL] [Abstract][Full Text] [Related]
14. Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.
Morsi N; Ghorab D; Refai H; Teba H
Int J Pharm; 2016 Jun; 506(1-2):57-67. PubMed ID: 27091293
[TBL] [Abstract][Full Text] [Related]
15. Physiologically activated phase transition systems for improved ocular retention of ketorolac tromethamine.
Thakor S; Vhora I; Desai J; Thakkar S; Thakkar H
J Pharm Bioallied Sci; 2012 Mar; 4(Suppl 1):S6-7. PubMed ID: 23066208
[TBL] [Abstract][Full Text] [Related]
16. Opioid-free analgesia following total knee arthroplasty--a multimodal approach using continuous lumbar plexus (psoas compartment) block, acetaminophen, and ketorolac.
Horlocker TT; Hebl JR; Kinney MA; Cabanela ME
Reg Anesth Pain Med; 2002; 27(1):105-8. PubMed ID: 11799514
[TBL] [Abstract][Full Text] [Related]
17. Pre-emptive injection of peri-articular-multimodal drug for post-operative pain management in total knee arthroplasty: a double-blind randomized clinical trial.
Motififard M; Omidian A; Badiei S
Int Orthop; 2017 May; 41(5):939-947. PubMed ID: 27904951
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies.
El-Setouhy DA; Ahmed S; Badawi AA; El-Nabarawi MA; Sallam N
Eur J Pharm Sci; 2015 Aug; 76():48-56. PubMed ID: 25917526
[TBL] [Abstract][Full Text] [Related]
19. Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications.
Soliman KA; Ullah K; Shah A; Jones DS; Singh TRR
Drug Discov Today; 2019 Aug; 24(8):1575-1586. PubMed ID: 31175956
[TBL] [Abstract][Full Text] [Related]
20. Delivery of bupivacaine from UHMWPE and its implications for managing pain after joint arthroplasty.
Grindy SC; Gil D; Suhardi JV; Muratoglu OK; Bedair H; Oral E
Acta Biomater; 2019 Jul; 93():63-73. PubMed ID: 31173960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
